Compare NMRA & FEIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMRA | FEIM |
|---|---|---|
| Founded | 2019 | 1961 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Electrical Products |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 554.0M | 494.3M |
| IPO Year | 2023 | 1994 |
| Metric | NMRA | FEIM |
|---|---|---|
| Price | $2.52 | $45.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 2 |
| Target Price | $6.57 | ★ $42.50 |
| AVG Volume (30 Days) | ★ 716.8K | 176.3K |
| Earning Date | 05-11-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 57.85 | ★ 316.95 |
| EPS | N/A | ★ 0.41 |
| Revenue | N/A | ★ $69,811,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $21.73 |
| P/E Ratio | ★ N/A | $114.59 |
| Revenue Growth | N/A | ★ 26.30 |
| 52 Week Low | $0.62 | $14.41 |
| 52 Week High | $3.65 | $61.47 |
| Indicator | NMRA | FEIM |
|---|---|---|
| Relative Strength Index (RSI) | 36.63 | 45.43 |
| Support Level | $2.35 | $26.29 |
| Resistance Level | $2.58 | $59.68 |
| Average True Range (ATR) | 0.19 | 4.24 |
| MACD | -0.09 | -0.43 |
| Stochastic Oscillator | 8.11 | 27.51 |
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.